Conceptus
This article was originally published in The Gray Sheet
Executive Summary
Developer of the STOP (selective tubal occlusion procedure) non-surgical permanent contraception device for women announces completion of a private placement of 1.9 mil. shares at $7.26 each. Net proceeds of $14 mil. will allow Conceptus to "continue to ramp up our pivotal trial of the STOP device, accelerate marketing in Australia and other international markets, and...invest in our manufacturing and distribution operations," the company says. PaineWebber served as placement agent
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.